GLUE 250117 7.50P (GLUE250117P7500) Stock Options, News & Quotes

English
中文繁體
中文简体

Download

Mobile

moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US OptionsDetailed Quotes

GLUE250117P7500

Watchlist

2.00
0.000.00%

15min DelayNot Open Jan 14 16:00 ET

0.00High0.00Low

Intraday

5D
Daily

No Data

News

Monte Rosa Therapeutics Provide Corporate Update, Key Milestones 2025
TipRanksJan 10 07:27 ET
Express News | Monte Rosa Therapeutics Says Initial Clinical Data From Phase 1 SAD/MAD Study of VAV1-directed Molecular Glue Degrader (MGD) MRT-6160 Expected In Q1 2025
BenzingaJan 10 07:16 ET
Express News | Monte Rosa Therapeutics: Year-End Cash & Equivalents Expected to Be $377 Mln as of Dec 31, 2024 and Anticipated to Fund Ops Into 2028
ReutersJan 10 07:05 ET
Express News | Monte Rosa Therapeutics: Mrt-8102, a Nek7-Directed Mgd Targeting Diseases Driven by Il-1Β & Nlrp3 Inflammasome, on Track for Ind Filing in H1 2025
ReutersJan 10 07:04 ET
Express News | Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2025
ReutersJan 10 07:00 ET
Monte Rosa Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
GlobeNewswireJan 6 07:00 ET

Comments

Trytosaveabit

Dec 11, 2024 06:52

Just a bit from the licensing agreement! Hehehe.

$Monte Rosa Therapeutics (GLUE.US)$ Novartis has agreed to pay Monte Rosa $150 million up front. Monte Rosa is eligible to receive up to $2.1 billion in development, regulatory, and sales milestones, beginning upon initiation of Phase 2 studies, as well as tiered royalties on ex-U.S. net sales. Monte Rosa will co-fund any Phase 3 clinical development and will share any profits and losses associated with the manufacturing and commercialization of MRT...

Trytosaveabit

Dec 11, 2024 06:26

Update! Watching for data! Today is Day 2!

$Monte Rosa Therapeutics (GLUE.US)$ Monte Rosa Therapeutics Announced It Will Present Preclinical Data On The Potential Of Its Highly Selective Cyclin-dependent Kinase 2 (Cdk2)-directed Molecular Glue Degrader To Treat Hr-positive/Her2-negative Breast Cancer At The 2024 San Antonio Breast Cancer Symposium

Trytosaveabit

Dec 11, 2024 06:10

Update

$Monte Rosa Therapeutics (GLUE.US)$ Reuters· 9 mins ago
Monte Rosa Therapeutics Announces Closing of Global License Agreement With Novartis to Advance T and B Cell-Modulating Vav1-Directed Molecular Glue Degraders

Jaguar8

Dec 11, 2024 06:07

ADDED NEWS

$Monte Rosa Therapeutics (GLUE.US)$
Monte Rosa Therapeutics Announces Closing of Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders
Monte Rosa Therapeutics (Nasdaq: GLUE) has closed its global exclusive development and commercialization license agreement with Novartis for VAV1-directed molecular glue degraders (MGDs), including MRT-6160. The deal includes a $150 million upfront paymentand potential earnings of up to $2.1 bill...

Jaguar8

Dec 11, 2024 06:07

NEWS

$Monte Rosa Therapeutics (GLUE.US)$
Monte Rosa Therapeutics Presents Preclinical Data at the 2024 San Antonio Breast Cancer Symposium on the Potential of its CDK2-directed Molecular Glue Degraders to Treat HR-positive/HER2-negative Breast Cancer
Monte Rosa Therapeutics (Nasdaq: GLUE) presented preclinical data on their CDK2-directed molecular glue degrader (MGD), MRT-9643, for treating HR-positive/HER2-negative breast cancer. The data shows that MRT-9643 demonstrates superior selectivity comp...